Moreover, this work provides a proof-of-concept to support that transplantations of MSCs with either genetic modification or pharmacological precondition-induced CXCR7 gain-of-function, potentially enhancing therapeutic efficacy during the treatment of RA. The gene discussed is ACKR3; the disease is rheumatoid arthritis.